- Home
- BCG vs KZR Comparison
BCG vs KZR Comparison
Compare BCG & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- KZR
- Stock Information
- Founded
- BCG 2016
- KZR 2015
- Country
- BCG United States
- KZR United States
- Employees
- BCG N/A
- KZR N/A
- Industry
- BCG
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- KZR Health Care
- Exchange
- BCG Nasdaq
- KZR Nasdaq
- Market Cap
- BCG 45.6M
- KZR 54.1M
- IPO Year
- BCG N/A
- KZR 2018
- Fundamental
- Price
- BCG $2.58
- KZR $6.45
- Analyst Decision
- BCG
- KZR Hold
- Analyst Count
- BCG 0
- KZR 2
- Target Price
- BCG N/A
- KZR $11.00
- AVG Volume (30 Days)
- BCG 76.8K
- KZR 61.0K
- Earning Date
- BCG 11-14-2024
- KZR 11-12-2024
- Dividend Yield
- BCG N/A
- KZR N/A
- EPS Growth
- BCG N/A
- KZR N/A
- EPS
- BCG N/A
- KZR N/A
- Revenue
- BCG $161,721,000.00
- KZR N/A
- Revenue This Year
- BCG N/A
- KZR N/A
- Revenue Next Year
- BCG N/A
- KZR N/A
- P/E Ratio
- BCG N/A
- KZR N/A
- Revenue Growth
- BCG N/A
- KZR N/A
- 52 Week Low
- BCG $1.85
- KZR $5.20
- 52 Week High
- BCG $16.61
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- KZR 28.75
- Support Level
- BCG N/A
- KZR $6.80
- Resistance Level
- BCG N/A
- KZR $7.04
- Average True Range (ATR)
- BCG 0.00
- KZR 0.24
- MACD
- BCG 0.00
- KZR -0.06
- Stochastic Oscillator
- BCG 0.00
- KZR 0.00
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.